{"id":"NCT03207750","sponsor":"GlaxoSmithKline","briefTitle":"This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine","officialTitle":"Immunogenicity, Reactogenicity and Safety Study of Pediarix®, Hiberix® and Prevenar 13® Co-administered With Two Different Formulations of GSK Biologicals' HRV Vaccine (444563) in Healthy Infants 6-12 Weeks of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-09-14","primaryCompletion":"2018-10-09","completion":"2019-03-01","firstPosted":"2017-07-05","resultsPosted":"2019-10-31","lastUpdate":"2020-12-29"},"enrollment":1280,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"PREVENTION"},"conditions":["Rotavirus Infection","Rotavirus Vaccines"],"interventions":[{"type":"BIOLOGICAL","name":"Rotarix","otherNames":["GSK Biologicals' PCV-free liquid formulation of oral live attenuated HRV vaccine.","GSK Biologicals' lyophilized formulation of oral live attenuated HRV vaccine."]},{"type":"BIOLOGICAL","name":"Pediarix","otherNames":["GSK Biologicals' Diphtheria and tetanus toxoids and acellular pertussis adsorbed","hepatitis B (recombinant) and inactivated poliovirus vaccine."]},{"type":"BIOLOGICAL","name":"Hiberix","otherNames":["GSK Biologicals' Haemophilus b conjugate vaccine (tetanus toxoid conjugate)"]},{"type":"BIOLOGICAL","name":"Prevenar 13","otherNames":["Pfizer's Pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 Protein)"]}],"arms":[{"label":"HRV PCV-free Liq Group","type":"EXPERIMENTAL"},{"label":"HRV Lyo Group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to assess if there is any immune interference between the Porcine circovirus free (PCV-free) liquid Human rotavirus (HRV) vaccine and routine infant vaccinations currently in use in the US, namely Pediarix®, Hiberix® and Prevenar 13® as compared to the currently licensed lyophilized formulation of the HRV vaccine when co-administered with the same routine vaccinations in healthy infants 6-12 weeks of age","primaryOutcome":{"measure":"Number of Seroprotected Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentrations Above or Equal to Cut-off Value.","timeFrame":"At Month 5 (One month after Dose 3 of co-administered vaccines)","effectByArm":[{"arm":"HRV Porcine Circovirus (PCV)-Free Liquid Group","deltaMin":478,"sd":null},{"arm":"HRV Lyophilized Group","deltaMin":486,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"6 Weeks","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":22},"locations":{"siteCount":47,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":632},"commonTop":["Irritability","Cough","Decreased appetite","Vomiting","Diarrhoea"]}}